<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000764</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00592-49</org_study_id>
    <nct_id>NCT03000764</nct_id>
  </id_info>
  <brief_title>RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer</brief_title>
  <acronym>SPLICI-Rad</acronym>
  <official_title>Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to seeking a molecular signature of pathological radiation
      induced fibrosis based on the response of skin fibroblasts after irradiation, comparing two
      groups of patients distinguished by their individual radiosensitivity. The signature will
      integrate recent insights in terms of alternative splicing of mRNAs and level of expression
      of non-coding RNAs, particularly long non-coding RNAs, snRNAs, snoRNAs and microRNAs. In each
      group each expression patterns of candidate HSP proteins potentially predictive of
      pathological radiation induced fibrosis (HSP27, HSP70, αβ crystalline) in the serum and on
      cell culture will be characterized.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global mRNA alternative splicing and expression of non-coding RNAs profiles in healthy dermal fibroblasts</measure>
    <time_frame>6 months</time_frame>
    <description>frequency of inclusion of individual exons within the set of mRNA isoforms (overall splicing profile) and variation in expression of non-coding RNAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on cultured fibroblasts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on serum</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual radiosensitivity on healthy dermal fibroblasts</measure>
    <time_frame>6 months</time_frame>
    <description>The micronuclei will be counted 24 hours after ex vivo irradiation with an indirect immunofluorescence assay (53BP1 + pATM antibodies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the overall mRNA splicing and non-coding RNA expression profiles between non irradiated and irradiated dermal fibroblasts in the same individual</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cellular distribution of the main non-coding RNAs whose expression varies significantly within the pre-identified signature between the 2 groups of patients</measure>
    <time_frame>6 months</time_frame>
    <description>The cellular distribution is defined as the compartment (nucleoplasm, nucleolus, intra-nuclear corpuscles, cytosol, RE, mitochondria ...) marked by the fluorescent probe labeled to the non-coding RNAs of interest (RNA-FISH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seric HSP proteins potentially predictive of pathological induced fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>HSP27, HSP70 and αB crystalline measured in serum with ELISA assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular distribution of specific HSP on fibroblast culture in each group of patients</measure>
    <time_frame>6 months</time_frame>
    <description>immunolabeling of HSPs and spatial mapping and sub-nuclear distributions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential interactions between DNA damage response proteins and candidate HSP</measure>
    <time_frame>6 months</time_frame>
    <description>Collocation of HSPs with pATM and 53-BP1 (confocal microscopy / FLIM)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Biomarkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsies</intervention_name>
    <description>Biopsies (12 G) will be performed :
in non-irradiated breast skin
in irradiated breast skin</description>
    <arm_group_label>Biomarkers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples are collected:
10 ml in EDTA tube
2,5 ml in PAXgene Blood RNA tube
4 ml in EDTA tube</description>
    <arm_group_label>Biomarkers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women

          -  age ≥ 18 and &lt;70 years old

          -  non metastatic disease

          -  ECOG performance status 0 or 1

          -  chest size ≤ 110 cm et bra size &lt;D

          -  absence of reconstructive breast surgery

          -  patient able to undergo blood samples (haematological conditions allowing blood
             sample)

          -  non-evolving carcinological disease

          -  absence of systemic inflammatory disease (other than scleroderma) or diabetes

          -  no inflammatory ou infectious flare on biopsy site at the time of inclusion

          -  invasive or in situ breast carcinoma

          -  ability to provide an informed written consent form

          -  affiliation to a social security system

        Then stratification into two groups :

        group 1 : radio-sensitive patients

          -  Post-operative radiotherapy completed at least 6 months ago AND

          -  radiation induced dermal and/or soft tissue toxicity (dermatitis, fibrosis, atrophy)
             rated &gt; 2 (CTCAE v4.0 scale)

        group 2 : radio-tolerant (control) patients

          -  Post-operative radiotherapy completed more than 4 years ago AND

          -  radiation induced dermal and/or soft tissue toxicity (dermatitis, fibrosis, atrophy)
             rated ≤1 (CTCAE v4.0 scale) .

        Exclusion Criteria:

          -  age &lt;18 or &gt; 70 years old

          -  evolutive cancer / metastatic disease

          -  chest size &gt; 110 cm et bra size ≥ D

          -  previous reconstructive breast surgery

          -  ECOG performance status &gt; 1

          -  systemic inflammatory disease or diabetes

          -  inflammatory ou infectious flare on biopsy site at the time of inclusion, very
             significant ulceration in the treated breast

          -  anemic patients

          -  use of oral anticoagulants

          -  pregnant or likely to be in 6 months

          -  patients deprived of liberty or under supervision

          -  non-affiliation to a social security system
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VOGIN GUILLAUME, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BEHM-ANSMANT Isabelle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMR 7365 CNRS-Université de Lorraine, IMoPA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS, Pr</last_name>
    <phone>0033383598307</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES LAURINDA</last_name>
    <phone>0033383598487</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VOGIN Guillaume, MD, PhD</last_name>
      <phone>+ 33 3 83 59 84 27</phone>
      <email>g.vogin@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>BEHM-ANSMANT Isabelle, PhD</last_name>
      <phone>+ 33 3 83 68 55 31</phone>
      <email>isabelle.behm@univ-lorraine.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin biopsy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>RNA biomarker</keyword>
  <keyword>HSP biomarker</keyword>
  <keyword>Exon junction array</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Radiosensitivity prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

